CA2322573A1 - Suivi non invasif du taux de glucose tissulaire - Google Patents
Suivi non invasif du taux de glucose tissulaire Download PDFInfo
- Publication number
- CA2322573A1 CA2322573A1 CA002322573A CA2322573A CA2322573A1 CA 2322573 A1 CA2322573 A1 CA 2322573A1 CA 002322573 A CA002322573 A CA 002322573A CA 2322573 A CA2322573 A CA 2322573A CA 2322573 A1 CA2322573 A1 CA 2322573A1
- Authority
- CA
- Canada
- Prior art keywords
- radiation
- instrument
- target
- glucose
- glucose level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 199
- 239000008103 glucose Substances 0.000 title claims abstract description 199
- 238000012544 monitoring process Methods 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 59
- 238000005259 measurement Methods 0.000 claims abstract description 17
- 230000005855 radiation Effects 0.000 claims description 111
- 210000001519 tissue Anatomy 0.000 claims description 71
- 239000011159 matrix material Substances 0.000 claims description 59
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 50
- 108010035532 Collagen Proteins 0.000 claims description 41
- 102000008186 Collagen Human genes 0.000 claims description 41
- 229920001436 collagen Polymers 0.000 claims description 41
- 206010012601 diabetes mellitus Diseases 0.000 claims description 31
- 230000008859 change Effects 0.000 claims description 28
- 230000005284 excitation Effects 0.000 claims description 28
- 102000004877 Insulin Human genes 0.000 claims description 25
- 108090001061 Insulin Proteins 0.000 claims description 25
- 229940125396 insulin Drugs 0.000 claims description 25
- 238000012545 processing Methods 0.000 claims description 20
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 18
- 239000000523 sample Substances 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 9
- 102000029816 Collagenase Human genes 0.000 claims description 5
- 108060005980 Collagenase Proteins 0.000 claims description 5
- 229960002424 collagenase Drugs 0.000 claims description 5
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 239000013305 flexible fiber Substances 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 102000057297 Pepsin A Human genes 0.000 claims description 2
- 108090000284 Pepsin A Proteins 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 229940111202 pepsin Drugs 0.000 claims description 2
- 239000010453 quartz Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims 4
- 230000005670 electromagnetic radiation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 239000012491 analyte Substances 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 43
- 239000008280 blood Substances 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 35
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 14
- 210000004207 dermis Anatomy 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 10
- 238000000695 excitation spectrum Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000003595 spectral effect Effects 0.000 description 6
- 230000004075 alteration Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 229910052724 xenon Inorganic materials 0.000 description 3
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- -1 lente Chemical compound 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000004497 NIR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000001434 dietary modification Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108010056686 glycosylated collagen Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002095 near-infrared Raman spectroscopy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000985 reflectance spectrum Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Emergency Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8079498P | 1998-04-06 | 1998-04-06 | |
| US60/080,794 | 1998-04-06 | ||
| PCT/US1999/007565 WO1999051142A2 (fr) | 1998-04-06 | 1999-04-06 | Suivi non invasif du taux de glucose tissulaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2322573A1 true CA2322573A1 (fr) | 1999-10-14 |
Family
ID=22159651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002322573A Abandoned CA2322573A1 (fr) | 1998-04-06 | 1999-04-06 | Suivi non invasif du taux de glucose tissulaire |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1069857A2 (fr) |
| JP (1) | JP2002510515A (fr) |
| AU (1) | AU766166B2 (fr) |
| CA (1) | CA2322573A1 (fr) |
| WO (1) | WO1999051142A2 (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544193B2 (en) | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
| US6505059B1 (en) * | 1998-04-06 | 2003-01-07 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
| US7899518B2 (en) | 1998-04-06 | 2011-03-01 | Masimo Laboratories, Inc. | Non-invasive tissue glucose level monitoring |
| US6728560B2 (en) | 1998-04-06 | 2004-04-27 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
| US6721582B2 (en) | 1999-04-06 | 2004-04-13 | Argose, Inc. | Non-invasive tissue glucose level monitoring |
| KR100675706B1 (ko) | 1999-08-26 | 2007-02-01 | 아이센스 아게 | 안구 분석물질 센서 |
| WO2001033201A1 (fr) | 1999-11-03 | 2001-05-10 | Argose, Inc. | Balayage a fluorescence asynchrone |
| WO2001033278A1 (fr) * | 1999-11-03 | 2001-05-10 | Argose, Inc. | Milieu d'interface pour echantillon de surface tissulaire |
| AU2001237066A1 (en) | 2000-02-18 | 2001-08-27 | Argose, Inc. | Generation of spatially-averaged excitation-emission map in heterogeneous tissue |
| US7043288B2 (en) * | 2002-04-04 | 2006-05-09 | Inlight Solutions, Inc. | Apparatus and method for spectroscopic analysis of tissue to detect diabetes in an individual |
| US7139598B2 (en) * | 2002-04-04 | 2006-11-21 | Veralight, Inc. | Determination of a measure of a glycation end-product or disease state using tissue fluorescence |
| US6549796B2 (en) * | 2001-05-25 | 2003-04-15 | Lifescan, Inc. | Monitoring analyte concentration using minimally invasive devices |
| IL164685A0 (en) | 2002-04-22 | 2005-12-18 | Marcio Marc Aurelio Martins Ab | Apparatus and method for measuring biologic parameters |
| US10123732B2 (en) | 2002-04-22 | 2018-11-13 | Geelux Holdings, Ltd. | Apparatus and method for measuring biologic parameters |
| US8328420B2 (en) | 2003-04-22 | 2012-12-11 | Marcio Marc Abreu | Apparatus and method for measuring biologic parameters |
| US8849379B2 (en) | 2002-04-22 | 2014-09-30 | Geelux Holdings, Ltd. | Apparatus and method for measuring biologic parameters |
| US7181219B2 (en) | 2003-05-22 | 2007-02-20 | Lucent Technologies Inc. | Wireless handover using anchor termination |
| US10227063B2 (en) | 2004-02-26 | 2019-03-12 | Geelux Holdings, Ltd. | Method and apparatus for biological evaluation |
| US8172459B2 (en) | 2005-10-24 | 2012-05-08 | Marcio Marc Abreu | Apparatus and method for measuring biologic parameters |
| DE102006026173A1 (de) * | 2006-06-06 | 2007-12-20 | Fachhochschule Südwestfalen | Verfahren zur nichtinvasiven Diagnose von Diabetes |
| JP5594786B2 (ja) * | 2008-04-21 | 2014-09-24 | ドレクセル・ユニバーシティー | 創傷が治癒しているかどうかを判定するために創傷組織の光学特性の変化を測定し、近赤外吸収（ｆＮＩＲ）および拡散反射分光散乱（ＤＲＳ）を、組織新血管新生およびコラーゲン濃度と相関させる方法 |
| WO2011040599A1 (fr) * | 2009-10-02 | 2011-04-07 | シャープ株式会社 | Dispositif destiné à la surveillance d'états de vaisseaux sanguins, et méthode de surveillance afférente |
| US9173604B2 (en) | 2010-03-19 | 2015-11-03 | Sharp Kabushiki Kaisha | Measurement device, measurement method, measurement result processing device, measurement system, measurement result processing method, control program, and recording medium |
| JP5808801B2 (ja) * | 2010-06-18 | 2015-11-10 | ディアフノプティクス ホールディング ベー．フェー． | 皮膚組織の自己蛍光値を求めるための方法および装置 |
| KR101243183B1 (ko) | 2011-04-08 | 2013-03-14 | 한국전기연구원 | 최종당화산물의 자가형광 측정 장치 |
| CA2927036A1 (fr) | 2013-10-11 | 2015-04-16 | Marcio Marc Abreu | Procede et appareil pour evaluation biologique |
| AU2015204588A1 (en) | 2014-01-10 | 2016-07-21 | Marcio Marc Abreu | Devices to monitor and provide treatment at an Abreu brain tunnel |
| AU2015204638A1 (en) | 2014-01-10 | 2016-07-21 | Marcio Marc Abreu | Device for measuring the infrared output of the Abreu brain thermal tunnel |
| JP2017503604A (ja) | 2014-01-22 | 2017-02-02 | マーシオ マーク アブリュー | Ａｂｒｅｕ脳熱トンネルでの治療を提供するように構成されたデバイス |
| CN106535626A (zh) * | 2014-05-21 | 2017-03-22 | 英派尔科技开发有限公司 | 用于动物生命周期监视的文身和文身施用器 |
| WO2016145215A1 (fr) | 2015-03-10 | 2016-09-15 | Marcio Marc Abreu | Dispositifs, appareils, systèmes et procédés pour mesurer la température d'une terminaison abtt |
| JP6156804B2 (ja) * | 2015-06-09 | 2017-07-05 | シャープライフサイエンス株式会社 | 老化評価装置 |
| AU2016381563B2 (en) * | 2015-12-31 | 2022-02-10 | Wear2B Ltd | Device, system and method for non-invasive monitoring of physiological measurements |
| JP2018105761A (ja) * | 2016-12-27 | 2018-07-05 | 東亜ディーケーケー株式会社 | 多波長蛍光分析装置 |
| JP2018146539A (ja) * | 2017-03-09 | 2018-09-20 | 東亜ディーケーケー株式会社 | 多波長蛍光分析装置 |
| US11896373B2 (en) * | 2017-05-22 | 2024-02-13 | Brolis Sensor Technology, Uab | Tunable hybrid III-V/ IV laser sensor system-on-a chip for real-time monitoring of a blood constituent concentration level |
| JP2020106318A (ja) * | 2018-12-26 | 2020-07-09 | メディカルフォトニクス株式会社 | 吸収カロリー計測装置、吸収カロリー計測方法、及び、吸収カロリー計測プログラム |
| CN112641429A (zh) * | 2020-12-24 | 2021-04-13 | 上海百雀羚生物科技有限公司 | 一种抗氧化效能的检测方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3837339A (en) * | 1972-02-03 | 1974-09-24 | Whittaker Corp | Blood glucose level monitoring-alarm system and method therefor |
| US4979509A (en) * | 1989-07-19 | 1990-12-25 | Northstar Research Institute, Ltd. | Continuous glucose monitoring and a system utilized therefor |
| US5341805A (en) * | 1993-04-06 | 1994-08-30 | Cedars-Sinai Medical Center | Glucose fluorescence monitor and method |
| AU6186494A (en) * | 1993-05-07 | 1994-11-10 | Diasense, Inc. | Non-invasive determination of analyte concentration using non-continuous radiation |
| WO1995006431A2 (fr) * | 1993-08-24 | 1995-03-09 | Robinson Mark R | Moniteur d'analyte solide, precis et non invasif |
| US5553616A (en) * | 1993-11-30 | 1996-09-10 | Florida Institute Of Technology | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator |
| US5492118A (en) * | 1993-12-16 | 1996-02-20 | Board Of Trustees Of The University Of Illinois | Determining material concentrations in tissues |
| DE4415896A1 (de) * | 1994-05-05 | 1995-11-09 | Boehringer Mannheim Gmbh | Analysesystem zur Überwachung der Konzentration eines Analyten im Blut eines Patienten |
-
1999
- 1999-04-06 EP EP99915314A patent/EP1069857A2/fr not_active Withdrawn
- 1999-04-06 WO PCT/US1999/007565 patent/WO1999051142A2/fr not_active Application Discontinuation
- 1999-04-06 AU AU33859/99A patent/AU766166B2/en not_active Ceased
- 1999-04-06 JP JP2000541918A patent/JP2002510515A/ja not_active Withdrawn
- 1999-04-06 CA CA002322573A patent/CA2322573A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1069857A2 (fr) | 2001-01-24 |
| JP2002510515A (ja) | 2002-04-09 |
| WO1999051142A2 (fr) | 1999-10-14 |
| WO1999051142A3 (fr) | 2000-02-17 |
| AU766166B2 (en) | 2003-10-09 |
| AU3385999A (en) | 1999-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6728560B2 (en) | Non-invasive tissue glucose level monitoring | |
| US6505059B1 (en) | Non-invasive tissue glucose level monitoring | |
| AU766166B2 (en) | Non-invasive tissue glucose level monitoring | |
| US7899518B2 (en) | Non-invasive tissue glucose level monitoring | |
| US6721582B2 (en) | Non-invasive tissue glucose level monitoring | |
| US20020091324A1 (en) | Non-invasive tissue glucose level monitoring | |
| US6741876B1 (en) | Method for determination of analytes using NIR, adjacent visible spectrum and discrete NIR wavelenths | |
| Vashist | Non-invasive glucose monitoring technology in diabetes management: A review | |
| US7139598B2 (en) | Determination of a measure of a glycation end-product or disease state using tissue fluorescence | |
| EP1467652B1 (fr) | Mesure indirecte d'analytes tissulaires par l'intermediaire de proprietes tissulaires | |
| US20140330098A1 (en) | Reflectance calibration of fluorescence-based glucose measurements | |
| JP2007516014A (ja) | グルコース決定と組み合わせた光刺激方法および装置 | |
| JP2007175514A (ja) | 体液成分濃度の生体内測定及び制御のための埋込可能センサー及びシステム | |
| US20120078075A1 (en) | Determination of a measure of a glycation end-product or disease state using tissue fluorescence in combination with one or more other tests | |
| CA2383725A1 (fr) | Procede de determination d'analytes au moyen d'un spectre en proche infrarouge, d'un spectre visible adjacent et de longueurs d'ondes distinctes de spectre en proche infrarouge | |
| JP3093871B2 (ja) | 光学的血糖値非破壊測定装置 | |
| AU2001238517A1 (en) | Non-invasive tissue glucose level monitoring | |
| Poddar et al. | Non-invasive glucose monitoring techniques: A review and current trends | |
| Blackwell et al. | In vivo time-resolved autofluorescence measurements to test for glycation of human skin | |
| EP1257196A1 (fr) | Controle non invasif du taux de glucose tissulaire | |
| JP2008522726A (ja) | 組織の生体内測定のための光サンプリングインタフェースシステム |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |